 Oral presentation to discuss new data updates from the high- and low-dose cohorts from the ongoing Phase 12 trial of AXO-AAV-GM1 for the treatment of GM1 gangliosidosis Oral presentation to discuss new data updates from the high- and low-dose cohorts from the ongoing Phase 12 trial of AXO-AAV-GM1 for the treatment of GM1 gangliosidosis 